Pegylation: engineering improved biopharmaceuticals for oncology.
about
Ribosome-inactivating proteins: from plant defense to tumor attackPharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyToward top-down determination of PEGylation site using MALDI in-source decay MS analysis.PEGylation of interleukin-10 for the mitigation of enhanced pain states.Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.Advances in strategies to improve drug delivery to brain tumors.In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG).Pharmacokinetics of pegfilgrastim.Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.Neutrophil biology and the next generation of myeloid growth factors.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Reproductive effects of a pegylated curcumin.Long-circulating polymeric nanovectors for tumor-selective gene delivery.Alphavbeta6 integrin in wound healing and cancer of the oral cavity.Strategies towards a longer acting factor VIII.Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.Haemophilia therapies.An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.Factors affecting the stability of drugs and drug metabolites in biological matrices.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.Cytokine binding by polysaccharide-antibody conjugates.Efficient microwave-assisted synthesis of amine-substituted tetrakis(pentafluorophenyl)porphyrinIschemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.Comparative analysis of polymer and linker chemistries on the efficacy of immunocamouflage of murine leukocytes.Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.Synthetic polymers as drugs and therapeuticsEngineering of magnetic DNA nanoparticles for tumor-targeted therapyRecent advances in "smart" delivery systems for extended drug release in cancer therapy
P2860
Q26828935-BBF24CA9-CC29-4464-9380-1AB0D5777506Q28083449-03542CEF-5DD6-46A7-8127-19E335E4202FQ33385574-A1B6AF82-F962-411B-9F60-048EBFEE5230Q33505369-A18F5852-2EC3-4EC6-AEF3-34C14ABDF201Q33858681-AB41F185-E026-46E7-B03A-E461F8EAFB7FQ34000631-8F8DC4C2-FEC9-4A59-BE5B-B628D9C150D6Q35079289-2470FD51-CEFE-47F7-AC2C-8389BB14967AQ35200820-134805F7-43D4-4847-85E4-EF259AD787EAQ35200824-6A63DE2A-6F62-46A7-9B27-6E03BA840649Q35653712-8A7B862E-36BF-4981-A809-3FEB29E1D5FCQ36039649-0296E448-C876-445C-A99F-3627DFA12EDFQ36070178-C42A1EE2-23DB-4DB2-9965-3D729856A824Q36314788-9D96A0D1-65E7-4ADD-96EC-ADACD53C0E50Q36360521-4B545E58-3728-4573-9721-A5AF4C697187Q36473043-F21BE390-63B3-4C42-8E72-C23FE0D6C0ACQ36697877-636B24B9-69CD-4DC1-86DF-A86B9E7D58E0Q36810282-C0060A8B-987A-4C2E-B122-4FC6AA4C14F2Q36837402-5A384647-4819-49A3-8E83-D7FF49A1ECFCQ37702246-44199954-48C5-48FA-B891-2799DCA5A502Q37708777-BA121C2C-56F5-4279-B335-D441DA0E564AQ37725990-A8A2934C-16B8-4DF0-8184-C1484A10551AQ37810212-25930A9F-B160-4F0F-9927-9F2751E280CBQ38126361-BDAC437B-19B5-4E32-9A9E-C752AB261B14Q38994917-4B19062F-E79D-4B0F-ACA8-6E74035A06CDQ39665229-D3569D28-C53D-4019-B3CD-35E1FE9F1317Q42101974-5AD4BA60-DFB9-4535-9514-CF27B8E07AEDQ42285332-C61A2AB5-0589-4762-B275-D8F3B4486465Q44019603-A444031B-61C6-4D0F-A8C4-2949293FFEA8Q44301366-864C90DD-D08E-4591-92E3-81F429DE5EBEQ46167729-175B2562-2713-41A1-97B4-1B3EDC7C3F1BQ49540233-574A0E9A-A4E1-41C8-8D41-498297CB96A2Q50962872-FBB3B55E-2C78-44EC-9B6A-D8987ED14104Q53677060-3950A1A5-2515-42F7-82F6-6099758D7C00Q57370215-3D649D91-8BCB-40AB-B8F4-C0A22DDF735AQ57920940-63D6A793-BAEC-4E82-A318-EEBCBC5D71ACQ58735813-372CE4DB-7CB8-413B-B127-F339918A6488
P2860
Pegylation: engineering improved biopharmaceuticals for oncology.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pegylation: engineering improved biopharmaceuticals for oncology.
@ast
Pegylation: engineering improved biopharmaceuticals for oncology.
@en
type
label
Pegylation: engineering improved biopharmaceuticals for oncology.
@ast
Pegylation: engineering improved biopharmaceuticals for oncology.
@en
prefLabel
Pegylation: engineering improved biopharmaceuticals for oncology.
@ast
Pegylation: engineering improved biopharmaceuticals for oncology.
@en
P2860
P1433
P1476
Pegylation: engineering improved biopharmaceuticals for oncology.
@en
P2093
Graham Molineux
P2860
P356
10.1592/PHCO.23.9.3S.32886
P407
P433
P577
2003-08-01T00:00:00Z